4:00-5:00 pm EST
Registration: https://form.jotform.com/91218739131961
To join webinar, visit: https://zoom.us/j/497517526
How will the recently-concluded United States-Mexico-Canada Agreement (USMCA) impact access to affordable medicines?
The USMCA – the renegotiated North American Free Trade Agreement (also commonly referred to as NAFTA 2.0) – incorporates many of the harmful provisions from the Trans Pacific Partnership (TPP), including patent provisions that were suspended by the remaining Parties following the withdrawal of the US. It goes even further than the TPP in extending the exclusivities for biologics to ten years, an unprecedented TRIPS-plus measure. Beyond the intellectual property chapter, multiple other chapters and provisions of the USMCA also have implications for access to affordable, safe and effective medicines.
In this upcoming webinar, we take a close look at the USMCA’s provisions and their potential impact.
Speakers:
Burcu Kilic, Public Citizen
Greed over Needs. NAFTA 2.0, Chapter 20: Highlights of Pharmaceutical- Related Patent Provisions
Joel Lexchin, York University
More Data Protection, More Spending: The Effects of the USMCA on How Much Canada Will Spend on Biologics
Deborah Gleeson, La Trobe University
Beyond Intellectual Property: Other Provisions in the USMCA with Implications for Pharmaceuticals
Chair: Mike Palmedo, American University
This is the first of a series of webinars planned by the FTA-Medicines-Empirics Network, an informal email network formed at the Global Congress on Intellectual Property and the Public Interest in 2018 to advance the empirical study of the impact of TRIPS-Plus Free Trade Agreements (and FTA provisions) on access to pharmaceuticals, vaccines, and diagnostics. To join the email list, visit tinyurl.com/fme-subscribe
Printable flyer for the webinar: https://tinyurl.com/nafta2-and-access-to-medicines
